Yazarlar : Lazenby M, Gilkes AF, Marrin C

Yayın : Leukemia.

Yayın Yılı : 2014

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/24573385

Konu : Geriyatrik Hematoloji

Literatür İçeriği :  Although the prognostic impact of mutations of FLT3 and NPM1 have been extensively studied in younger patients with acute myeloid leukaemia, less is known in older patients whether treated intensively or non-intensively, or in the context of existing prognostic scores. In 1312 patients 16% and 21% respectively had a FLT3 and NPM1 mutation. A FLT3 mutation did not affect remission rate in intensively or non-intensively treated patients but was associated with an inferior survival. All patients with an NPM1c mutation had a significantly higher remission rate irrespective of treatment approach but survival was not improved, overall, or in any genotype except as in younger patients, in the FLT3 WT NPM1c mutant subgroup. When incorporated into an established multi-parameter prognostic risk score the molecular information provided additional prognostic definition in 11% of patients.Leukemia accepted article preview online, 27 February 2014; doi:10.1038/leu.2014.90.

Literatür Arşivi